Gastric Cancer
News
Herceptin® Improves Survival with HER2-positive Gastric Cancer
(06/02/2009)
According to the results of a Phase III clinical trial presented at the 2009 annual meeting of the American Society of Clinical Oncology (ASCO), treatment with a combination of chemotherapy and the targeted drug Herceptin® (trastuzumab) results in better survival than chemotherapy alone among patients with advanced, HER2-positive gastric (stomach) cancer.
Laparoscopic Surgery Results in Fewer Complications for Patients with Stomach Cancer
(05/08/2009)
Laparoscopic surgery produces a similar rate of recurrence-free survival as traditional open surgery in patients with gastric cancer but results in fewer complications and shorter hospital stays, according to the results of a study published in the Annals of Surgical Oncology.
Herceptin® Improves Survival with HER2-positive Stomach Cancer
(03/31/2009)
According to the results of a Phase III clinical trial, treatment with the targeted therapy Herceptin® (trastuzumab) improves survival among patients with HER2-positive, advanced and inoperable stomach cancer. These results were made available in a press release from Roche.
In Gastric Cancer Antibiotics Following Surgery Reduce Risk of Second Gastric Cancer
(08/04/2008)
Among patients diagnosed with gastric (stomach) cancer, a combination of antibiotics against the bacterium Helicobacter pylori (H. pylori) significantly reduces the risk of developing a second gastric cancer. These results were recently published in the August 2008 issue of Lancet Oncology.
Removal of More Lymph Nodes May Improve Survival in Gastric and Pancreatic Cancers
(07/23/2008)
Researchers recommend that at least 15 lymph nodes be removed and examined in patients with early gastric or pancreatic cancers. These results were recently published in the Archives of Surgery.
More
Gastric Cancer
Cancer News...